Literature DB >> 32198729

In silico analyses of the tumor microenvironment highlight tumoral inflammation, a Th2 cytokine shift and a mesenchymal stem cell-like phenotype in advanced in basal cell carcinomas.

Philippe Lefrançois1, Pingxing Xie2, Scott Gunn2, Jennifer Gantchev2, Amelia Martínez Villarreal2, Denis Sasseville2, Ivan V Litvinov3.   

Abstract

Basal Cell Carcinoma (BCC) represents the most common form of all cancers. BCC is characteristically surrounded by a fibromyxoid stroma. Previous studies have suggested a shift towards a Th2 response, an increase in T regulatory lymphocytes and the presence of cancer-associated fibroblasts in the BCC tumor microenvironment. In this study, we aimed to further characterize the BCC tumor microenvironment in detail by analyzing BCC RNA-Sequencing data and correlating it with clinically-relevant features via in silico RNA deconvolution. Using immune cell type deconvolution by CIBERSORT, we have identified a brisk lymphocytic infiltration, and more abundant macrophages in BCC tumors compared to normal skin. Using cell type enrichment by xCell, we confirmed the observed immune infiltration in BCC tumors and compared them to normal skin. We observed a shift towards Th2 immunity in advanced and vismodegib-resistant tumors. Tumoral inflammation induced by macrophage activity was associated with advanced BCCs, while lymphocytic infiltration was most significant in non-advanced tumors, likely related to an adaptive anti-tumoral response. In advanced and vismodegib-resistant BCCs, mesenchymal stem cell-like properties were observed. Particularly in vismodegib-resistant BCCs, fibroblasts and adipocytes were found at high number, which ultimately may contribute to the decreased drug delivery to the tumor. In conclusion, this study has revealed notable BCC tumor microenvironment findings associated with important clinical features. Microenvironment-altering agents may be used locally for "routine" BCCs and systematically for advanced or resistant BCCs.

Entities:  

Keywords:  Basal Cell Carcinoma (BCC); CIBERSORT; Tumor microenvironment; Vismodegib; xCell

Year:  2020        PMID: 32198729     DOI: 10.1007/s12079-020-00563-6

Source DB:  PubMed          Journal:  J Cell Commun Signal        ISSN: 1873-9601            Impact factor:   5.782


  6 in total

1.  Pan-Cancer Analyses Reveal Oncogenic and Immunological Role of Dickkopf-1 (DKK1).

Authors:  Shuang Gao; Ye Jin; Hongmei Zhang
Journal:  Front Genet       Date:  2021-11-24       Impact factor: 4.599

Review 2.  The Contributions of Cancer-Testis and Developmental Genes to the Pathogenesis of Keratinocyte Carcinomas.

Authors:  Brandon Ramchatesingh; Jennifer Gantchev; Amelia Martínez Villarreal; Raman Preet Kaur Gill; Marine Lambert; Sriraam Sivachandran; Philippe Lefrançois; Ivan V Litvinov
Journal:  Cancers (Basel)       Date:  2022-07-26       Impact factor: 6.575

3.  Nodular and Micronodular Basal Cell Carcinoma Subtypes Are Different Tumors Based on Their Morphological Architecture and Their Interaction with the Surrounding Stroma.

Authors:  Mircea-Sebastian Șerbănescu; Raluca Maria Bungărdean; Carmen Georgiu; Maria Crișan
Journal:  Diagnostics (Basel)       Date:  2022-07-05

4.  In silico Identification of Immune Cell-Types and Pathways Involved in Chronic Spontaneous Urticaria.

Authors:  Connor Prosty; Sofianne Gabrielli; Moshe Ben-Shoshan; Michelle Le; Ana M Giménez-Arnau; Ivan V Litvinov; Philippe Lefrançois; Elena Netchiporouk
Journal:  Front Med (Lausanne)       Date:  2022-07-07

Review 5.  Dickkopf-1: A Promising Target for Cancer Immunotherapy.

Authors:  Hang Yin Chu; Zihao Chen; Luyao Wang; Zong-Kang Zhang; Xinhuan Tan; Shuangshuang Liu; Bao-Ting Zhang; Aiping Lu; Yuanyuan Yu; Ge Zhang
Journal:  Front Immunol       Date:  2021-05-20       Impact factor: 7.561

Review 6.  Integrin αE(CD103)β7 in Epithelial Cancer.

Authors:  Johanna C Hoffmann; Michael P Schön
Journal:  Cancers (Basel)       Date:  2021-12-09       Impact factor: 6.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.